<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US5969156 - Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl ... - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)"><meta name="DC.contributor" content="Christopher A. Briggs" scheme="inventor"><meta name="DC.contributor" content="Rex A. Jennings" scheme="inventor"><meta name="DC.contributor" content="Robert Wade" scheme="inventor"><meta name="DC.contributor" content="Kikuko Harasawa" scheme="inventor"><meta name="DC.contributor" content="Shigeru Ichikawa" scheme="inventor"><meta name="DC.contributor" content="Kazuo Minohara" scheme="inventor"><meta name="DC.contributor" content="Shinsuke Nakagawa" scheme="inventor"><meta name="DC.contributor" content="Warner-Lambert Company" scheme="assignee"><meta name="DC.date" content="1996-7-8" scheme="dateSubmitted"><meta name="DC.description" content="Crystalline forms of atorvastatin and hydrates thereof are useful hypolipidemic and hypocholesterolemic agents."><meta name="DC.date" content="1999-10-19" scheme="issued"><meta name="DC.relation" content="EP:0409281:A1" scheme="references"><meta name="DC.relation" content="US:5316765" scheme="references"><meta name="DC.relation" content="WO:1994016693:A1" scheme="references"><meta name="citation_reference" content="Bocan, Thomas et al., Antiaherosclerotic activity of inhibitors of 3 hydroxy 3 methylgutaryl coenzyme A reductase, Atherosclerosis, 111, 127 142, Dec. 1994."><meta name="citation_reference" content="Bocan, Thomas et al., Antiaherosclerotic activity of inhibitors of 3-hydroxy-3-methylgutaryl coenzyme A reductase, Atherosclerosis, 111, 127-142, Dec. 1994."><meta name="citation_reference" content="Pharmaceutical Research , vol. 10, No. 10, 1993, pp. 1461 1465, Kearney, et al."><meta name="citation_reference" content="Pharmaceutical Research, vol. 10, No. 10, 1993, pp. 1461-1465, Kearney, et al."><meta name="citation_reference" content="Tetrahedron Letters , vol. 33, No. 17, 1992, pp. 2283 2284, Baumann, et al."><meta name="citation_reference" content="Tetrahedron Letters, vol. 33, No. 17, 1992, pp. 2283-2284, Baumann, et al."><meta name="citation_patent_number" content="US:5969156"><meta name="citation_patent_application_number" content="US:08/945,812"><link rel="canonical" href="http://www.google.com/patents/US5969156"/><meta property="og:url" content="http://www.google.com/patents/US5969156"/><meta name="title" content="Patent US5969156 - Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)"/><meta name="description" content="Crystalline forms of atorvastatin and hydrates thereof are useful hypolipidemic and hypocholesterolemic agents."/><meta property="og:title" content="Patent US5969156 - Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("XijuU7DEI4HQsQT51oH4DA"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("PRT"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("XijuU7DEI4HQsQT51oH4DA"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("PRT"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us5969156?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US5969156"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=4Z5MBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS5969156&amp;usg=AFQjCNHTlQmAC9Za0P4j8dVhE4YiUrFPqg" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US5969156.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US5969156.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US5969156" style="display:none"><span itemprop="description">Crystalline forms of atorvastatin and hydrates thereof are useful hypolipidemic and hypocholesterolemic agents....</span><span itemprop="url">http://www.google.com/patents/US5969156?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US5969156 - Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US5969156 - Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)" title="Patent US5969156 - Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US5969156 A</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 08/945,812</td></tr><tr><td class="patent-bibdata-heading">PCT number</td><td class="single-patent-bibdata">PCT/US1996/011368</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Oct 19, 1999</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Jul 8, 1996</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Jul 17, 1995</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA2220018A1">CA2220018A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/CA2220018C">CA2220018C</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1087288C">CN1087288C</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1190955A">CN1190955A</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69616808D1">DE69616808D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69616808T2">DE69616808T2</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69634054D1">DE69634054D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69634054T2">DE69634054T2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0848705A1">EP0848705A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0848705B1">EP0848705B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1148049A1">EP1148049A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1148049B1">EP1148049B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO1997003959A1">WO1997003959A1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">08945812, </span><span class="patent-bibdata-value">945812, </span><span class="patent-bibdata-value">PCT/1996/11368, </span><span class="patent-bibdata-value">PCT/US/1996/011368, </span><span class="patent-bibdata-value">PCT/US/1996/11368, </span><span class="patent-bibdata-value">PCT/US/96/011368, </span><span class="patent-bibdata-value">PCT/US/96/11368, </span><span class="patent-bibdata-value">PCT/US1996/011368, </span><span class="patent-bibdata-value">PCT/US1996/11368, </span><span class="patent-bibdata-value">PCT/US1996011368, </span><span class="patent-bibdata-value">PCT/US199611368, </span><span class="patent-bibdata-value">PCT/US96/011368, </span><span class="patent-bibdata-value">PCT/US96/11368, </span><span class="patent-bibdata-value">PCT/US96011368, </span><span class="patent-bibdata-value">PCT/US9611368, </span><span class="patent-bibdata-value">US 5969156 A, </span><span class="patent-bibdata-value">US 5969156A, </span><span class="patent-bibdata-value">US-A-5969156, </span><span class="patent-bibdata-value">US5969156 A, </span><span class="patent-bibdata-value">US5969156A</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Christopher+A.+Briggs%22">Christopher A. Briggs</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Rex+A.+Jennings%22">Rex A. Jennings</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Robert+Wade%22">Robert Wade</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Kikuko+Harasawa%22">Kikuko Harasawa</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Shigeru+Ichikawa%22">Shigeru Ichikawa</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Kazuo+Minohara%22">Kazuo Minohara</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Shinsuke+Nakagawa%22">Shinsuke Nakagawa</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Warner-Lambert+Company%22">Warner-Lambert Company</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US5969156.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5969156.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5969156.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (3),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (6),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (114),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (12),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (9)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=4Z5MBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/5969156&usg=AFQjCNG0XHXuXAEnx-sXR3ITQf_gdgHe2w">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=4Z5MBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D5969156&usg=AFQjCNHRKNG3-rCXi1CKDepO3_BV0M5Hgw">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=4Z5MBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D5969156A%26KC%3DA%26FT%3DD&usg=AFQjCNE-g8qn0wAucBPtq95aJBMhxGpFkA">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT70382375" lang="EN" load-source="patent-office">Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)</invention-title></span><br><span class="patent-number">US 5969156 A</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA37975594" lang="EN" load-source="patent-office"> <div class="abstract">Crystalline forms of atorvastatin and hydrates thereof are useful hypolipidemic and hypocholesterolemic agents.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(6)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5969156-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5969156-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5969156-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5969156-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5969156-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5969156-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5969156-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5969156-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5969156-5.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5969156-5.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5969156-6.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5969156-6.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(44)</span></span></div><div class="patent-text"><div mxw-id="PCLM59528364" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>We claim:</claim-statement> <div class="claim"> <div num="1" class="claim">
      <div class="claim-text">1. A crystalline Form I atorvastatin hydrate having an X-ray powder diffraction containing at least one of the following 2θ values measured using CuK.sub.α  radiation: 11.9 or 22.0.</div>
    </div>
    </div> <div class="claim"> <div num="2" class="claim">
      <div class="claim-text">2. A crystalline Form I atorvastatin hydrate having an X-ray powder diffraction containing the following 2θ values measured using Cuk.sub.α  radiation: 11.9, 21.6 and 22.0.</div>
    </div>
    </div> <div class="claim"> <div num="3" class="claim">
      <div class="claim-text">3. A crystalline Form I atorvastatin hydrate having an X-ray powder diffraction containing the following 2θ values measured using CuK.sub.α  radiation: 17.1, 19.5 and 21.6.</div>
    </div>
    </div> <div class="claim"> <div num="4" class="claim">
      <div class="claim-text">4. A crystalline Form I atorvastatin hydrate having an X-ray powder diffraction containing the following 2θ values measured using Cuk.sub.α  radiation: 9.2, 9.5, 10.3, 10.6, 11.9, 12.2, 17.1, 19.5, 21.6, 22.0, 22.7, 23.3, 23.7, 24.4, 28.9 and 29.2.</div>
    </div>
    </div> <div class="claim"> <div num="5" class="claim">
      <div class="claim-text">5. A crystalline Form I atorvastatin hydrate having an X-ray powder diffraction containing the following 2θ values measured using Cuk.sub.α  radiation: 9.150, 9.470, 10.266, 10.560, 11.853, 12.195, 17.075, 19.485, 21.626, 21.960, 22.748, 23.335, 23.734, 24.438, 28.915 and 29.234.</div>
    </div>
    </div> <div class="claim"> <div num="6" class="claim">
      <div class="claim-text">6. A crystalline Form I atorvastatin hydrate characterized by solid state <sup>13</sup> C nuclear magnetic resonance having a chemical shift difference between the lowest ppm resonance and another resonance of 5.1 or 51.8.</div>
    </div>
    </div> <div class="claim"> <div num="7" class="claim">
      <div class="claim-text">7. A crystalline Form I atorvastatin hydrate characterized by solid state <sup>13</sup> C nuclear magnetic resonance and having the following chemical shift differences between the lowest ppm resonance and other resonances: 3.9, 5.1, 43.6, 46.8, 49.2 and 51.8.</div>
    </div>
    </div> <div class="claim"> <div num="8" class="claim">
      <div class="claim-text">8. A crystalline Form I atorvastatin hydrate characterized by solid-state <sup>13</sup> C nuclear magnetic resonance having the following chemical shift differences between the lowest ppm resonance and other resonances: 3.9, 5.1, 18.9, 20.6, 26.1, 43.6, 46.8, 49.2, 51.8, 92.5, 96.9, 99.6, 102.2, 106.3, 108.2, 109.8, 113.6, 115.7, 138.0, 145.4, 157.1 and 161.5.</div>
    </div>
    </div> <div class="claim"> <div num="9" class="claim">
      <div class="claim-text">9. A crystalline Form I atorvastatin hydrate characterized by solid-state <sup>13</sup> C nuclear magnetic resonance having the following chemical shifts expressed in parts per million: 21.3. 25.2, 26.4, 40.2, 41.9, 47.4, 64.9, 68.1, 70.5, 73.1, 113.8, 118.2, 120.9, 123.5, 127.6, 129.5, 131.1, 134.9, 137.0, 159.3, 166.7 (broad), 178.4 and 182.8.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="10" class="claim">
      <div class="claim-text">10. The crystalline Form I atorvastatin hydrate of claim 1 containing about 1 to 8 moles of water.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="11" class="claim">
      <div class="claim-text">11. The crystalline Form I atorvastatin hydrate of claim 1 containing 3 moles of water.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="12" class="claim">
      <div class="claim-text">12. The crystalline Form I atorvastatin hydrate of claim 2 containing about 1 to 8 moles of water.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="13" class="claim">
      <div class="claim-text">13. The crystalline Form I atorvastatin hydrate of claim 2 containing 3 moles of water.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="14" class="claim">
      <div class="claim-text">14. The crystalline Form I atorvastatin hydrate of claim 3 containing about 1 to 8 moles of water.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="15" class="claim">
      <div class="claim-text">15. The crystalline Form I atorvastatin hydrate of claim 3 containing 3 moles of water.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="16" class="claim">
      <div class="claim-text">16. The crystalline Form I atorvastatin hydrate of claim 4 containing about 1 to 8 moles of water.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="17" class="claim">
      <div class="claim-text">17. The crystalline Form I atorvastatin hydrate of claim 4 containing 3 moles of water.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="18" class="claim">
      <div class="claim-text">18. The crystalline Form I atorvastatin hydrate of claim 5 containing about 1 to 8 moles of water.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="19" class="claim">
      <div class="claim-text">19. The crystalline Form I atorvastatin hydrate of claim 5 containing 3 moles of water.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="20" class="claim">
      <div class="claim-text">20. The crystalline Form I atorvastatin hydrate of claim 6 containing about 1 to 8 moles of water.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="21" class="claim">
      <div class="claim-text">21. The crystalline Form I atorvastatin hydrate of claim 6 containing 3 moles of water.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="22" class="claim">
      <div class="claim-text">22. The crystalline Form I atorvastatin hydrate of claim 7 containing about 1 to 8 moles of water.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="23" class="claim">
      <div class="claim-text">23. The crystalline Form I atorvastatin hydrate of claim 7 containing 3 moles of water.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="24" class="claim">
      <div class="claim-text">24. The crystalline Form I atorvastatin hydrate of claim 8 containing about 1 to 8 moles of water.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="25" class="claim">
      <div class="claim-text">25. The crystalline Form I atorvastatin hydrate of claim 8 containing 3 moles of water.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="26" class="claim">
      <div class="claim-text">26. The crystalline Form I atorvastatin hydrate of claim 9 containing about 1 to 8 moles of water.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="27" class="claim">
      <div class="claim-text">27. The crystalline Form I atorvastatin hydrate of claim 9 containing 3 moles of water.</div>
    </div>
    </div> <div class="claim"> <div num="28" class="claim">
      <div class="claim-text">28. Crystalline Form II atorvastatin or a hydrate thereof having an X-ray powder diffraction containing the following 2θ values measured using CuK.sub.α  radiation: 9.0 and 20.5.</div>
    </div>
    </div> <div class="claim"> <div num="29" class="claim">
      <div class="claim-text">29. Crystalline Form II atorvastatin or a hydrate thereof having an X-ray powder diffraction containing the following 2θ values measured using CuK.sub.α  radiation: 8.5 and 9.0.</div>
    </div>
    </div> <div class="claim"> <div num="30" class="claim">
      <div class="claim-text">30. Crystalline Form II atorvastatin or a hydrate thereof having an X-ray powder diffraction containing the following 2θ values measured using CuK.sub.α  radiation: 5.6, 7.4, 8.5, 9.0, 12.4 (broad), 15.8 (broad), 17.1-17.4 (broad), 19.5, 20.5, 22.7-23.2 (broad), 25.7 (broad) and 29.5.</div>
    </div>
    </div> <div class="claim"> <div num="31" class="claim">
      <div class="claim-text">31. Crystalline Form II atorvastatin or a hydrate thereof having an X-ray powder diffraction containing the following 2θ values measured using Cuk.sub.α  radiation: 5.582, 7.384, 8.533, 9.040, 12.440 (broad), 15.771 (broad), 17.120-17.360 (broad), 19.490, 20.502, 22.706-23.159 (broad), 25.697 (broad) and 29.504.</div>
    </div>
    </div> <div class="claim"> <div num="32" class="claim">
      <div class="claim-text">32. Crystalline Form II atorvastatin or a hydrate thereof characterized by solid state <sup>13</sup> C nuclear magnetic resonance having a chemical shift difference between the lowest ppm resonance and another resonance of 4.7 or 47.8.</div>
    </div>
    </div> <div class="claim"> <div num="33" class="claim">
      <div class="claim-text">33. Crystalline Form II atorvastatin or a hydrate thereof characterized by solid state <sup>13</sup> C nuclear magnetic resonance having the following chemical shift differences between the lowest ppm resonance and other resonances: 4.7, 44.5, 45.2, 46.2 and 47.8.</div>
    </div>
    </div> <div class="claim"> <div num="34" class="claim">
      <div class="claim-text">34. Crystalline Form II atorvastatin or a hydrate thereof characterized by solid-state <sup>13</sup> C nuclear magnetic resonance having the following chemical shift differences between the lowest ppm resonance and other resonances: 4.7, 17.4, 18.9, 19.5, 20.6, 44.5, 45.2, 46.2, 47.8, 91.9, 92.9, 94.3, 96.2, 97.5, 98.6, 100.1, 106.2, 110.5, 112.0, 117.7, 138.2, 140.2 and 158.2.</div>
    </div>
    </div> <div class="claim"> <div num="35" class="claim">
      <div class="claim-text">35. Crystalline Form II atorvastatin or a hydrate thereof characterized by solid-state <sup>13</sup> C nuclear magnetic resonance having the following chemical shifts expressed in parts per million: 22.8 (broad), 27.5, 40.2, 41.7, 42.3, 43.4, 67.3, 68.0, 69.0, 70.6, 114.7, 115.7, 117.1, 119.0, 120.3, 121.4, 122.9, 129.0, 133.3, 134.8, 140.5, 161 (broad), 163 (broad) and 181 (broad).</div>
    </div>
    </div> <div class="claim"> <div num="36" class="claim">
      <div class="claim-text">36. Crystalline Form IV atorvastatin or a hydrate thereof having an X-ray powder diffraction containing at least one of the following 2θ values measured using CuK.sub.α  radiation: 8.0 or 9.7.</div>
    </div>
    </div> <div class="claim"> <div num="37" class="claim">
      <div class="claim-text">37. Crystalline Form IV atorvastatin or a hydrate thereof having an X-ray powder diffraction containing the following 2θ values measured using CuK.sub.α  radiation: 4.9, 8.0 and 9.7.</div>
    </div>
    </div> <div class="claim"> <div num="38" class="claim">
      <div class="claim-text">38. Crystalline Form IV atorvastatin or a hydrate thereof having an X-ray powder diffraction containing the following 2θ values measured using CuK.sub.α  radiation: 8.0, 9.7 and 19.6.</div>
    </div>
    </div> <div class="claim"> <div num="39" class="claim">
      <div class="claim-text">39. Crystalline Form IV atorvastatin or a hydrate thereof having an X-ray powder diffraction containing the following 2θ values measured using CuK.sub.α  radiation: 4.9, 5.4, 5.9, 8.0, 9.7, 10.4, 12.4, 17.7, 18.4, 19.2, 19.6, 21.7, 23.0, 23.7 and 24.1.</div>
    </div>
    </div> <div class="claim"> <div num="40" class="claim">
      <div class="claim-text">40. Crystalline Form IV atorvastatin or a hydrate thereof having an X-ray powder diffraction containing the following 2θ values measured using CuK.sub.α  radiation: 4.889, 5.424, 5.940, 7.997, 9.680, 10.416, 12.355, 17.662, 18.367, 19.200, 19.569, 21.723, 23.021, 23.651 and 24.143.</div>
    </div>
    </div> <div class="claim"> <div num="41" class="claim">
      <div class="claim-text">41. Crystalline Form IV atorvastatin or a hydrate thereof characterized by solid state <sup>13</sup> C nuclear magnetic resonance having a chemical shift difference between the lowest ppm resonance and another resonance of 8.0 or 53.6.</div>
    </div>
    </div> <div class="claim"> <div num="42" class="claim">
      <div class="claim-text">42. Crystalline Form IV atorvastatin or a hydrate thereof characterized by solid state <sup>13</sup> C nuclear magnetic resonance having the following chemical shift differences between the lowest ppm resonance and other resonances: 1.5, 2.4, 8.0, 45.6, 48.4, 50.0 and 53.6.</div>
    </div>
    </div> <div class="claim"> <div num="43" class="claim">
      <div class="claim-text">43. Crystalline Form IV atorvastatin or a hydrate thereof characterized by solid-state <sup>13</sup> C nuclear magnetic resonance having the following chemical shift differences between the lowest ppm resonance and other resonances: 1.5, 2.4, 8.0, 22.1, 24.2, 25.5, 28.2, 45.6, 48.4, 50.0, 53.6, 97.8, 101.9, 104.8, 109.2, 111.3, 116.8, 120.2, 141.1, 148.2, 161.4, 163.5, 167.0 and 168.5.</div>
    </div>
    </div> <div class="claim"> <div num="44" class="claim">
      <div class="claim-text">44. Crystalline Form IV atorvastatin or a hydrate thereof characterized by solid-state <sup>13</sup> C nuclear magnetic resonance having the following chemical shifts expressed in parts per million: 17.9, 19.4, 20.3, 25.9, 40.0, 42.1, 43.4, 46.1, 63.5, 66.3, 67.9, 71.5, 115.7, 119.8, 122.7, 127.1,129.2, 134.7, 138.1 (broad), 159.0 (broad), 166.1 (broad), 179.3, 181.4, 184.9 and 186.4.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES67352804" lang="EN" load-source="patent-office" class="description">
    <p>This application is a 371 of PCT/US96/11368 filed Jul. 8, 1996 which is a continuation of Provisional Application No. Ser. 60/001,452, filed Jul. 17, 1995.</p>
    <heading>BACKGROUND OF THE INVENTION</heading> <p>The present invention relates to novel crystalline forms of atorvastatin which is known by the chemical name [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt useful as pharmaceutical agents, to methods for their production and isolation, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to pharmaceutical methods of treatment. The novel crystalline compounds of the present invention are useful as inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) and are thus useful hypolipidemic and hypocholesterolemic agents.</p>
    <p>U.S. Pat. No. 4,681,893, which is herein incorporated by reference, discloses certain trans-6-[2-(3- or 4-carboxamido-substituted-pyrrol-1-yl)alkyl]-4-hydroxy-pyran-2-ones including trans (±)-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[(2-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide.</p>
    <p>U.S. Pat. No. 5,273,995, which is herein incorporated by reference, discloses the enantiomer having the R form of the ring-opened acid of trans-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[(2-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide, i.e., [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid.</p>
    <p>U.S. Pat. Nos. 5,003,080; 5,097,045; 5,103,024; 5,124,482; 5,149,837; 5,155,251; 5,216,174; 5,245,047; 5,248,793; 5,280,126; 5,397,792; and 5,342,952, which are herein incorporated by reference, disclose various processes and key intermediates for preparing atorvastatin.</p>
    <p>Atorvastatin is prepared as its calcium salt, i.e., [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1). The calcium salt is desirable since it enables atorvastatin to be conveniently formulated in, for example, tablets, capsules, lozenges, powders, and the like for oral administration. Additionally, there is a need to produce atorvastatin in a pure and crystalline form to enable formulations to meet exacting pharmaceutical requirements and specifications.</p>
    <p>Furthermore, the process by which atorvastatin is produced needs to be one which is amenable to large-scale production. Additionally, it is desirable that the product should be in a form that is readily filterable and easily dried. Finally, it is economically desirable that the product be stable for extended periods of time without the need for specialized storage conditions.</p>
    <p>The processes in the above United States Patents disclose amorphous atorvastatin which has unsuitable filtration and drying characteristics for large-scale production and must be protected from heat, light, oxygen, and moisture.</p>
    <p>We have now surprisingly and unexpectedly found that atorvastatin can be prepared in crystalline form. Thus, the present invention provides atorvastatin in new crystalline forms designated Form I, Form II, and Form IV. Form I atorvastatin consists of smaller particles and a more uniform size distribution than the previous amorphous product and exhibits more favorable filtration and drying characteristics. Additionally, Form I atorvastatin is purer and more stable than the amorphous product.</p>
    <heading>SUMMARY OF THE INVENTION</heading> <p>Accordingly, the present invention is directed to crystalline Form I atorvastatin and hydrates thereof characterized by the following X-ray powder diffraction pattern expressed in terms of the 2θ, d-spacings, and relative intensities with a relative intensity of &gt;20% measured after 2 minutes of grinding and measured on a Siemens D-500 diffractometer with CuK.sub.α   radiation:</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">______________________________________                 Relative    Intensity    (&gt;20%) Ground  2θ d 2 Minutes______________________________________ 9.150        9.6565  42.60   9.470 9.3311 41.94  10.266 8.6098 55.67  10.560 8.3705 29.33  11.853 7.4601 41.74  12.195 7.2518 24.62  17.075 5.1887 60.12  19.485 4.5520 73.59  21.626 4.1059 100.00  21.960 4.0442 49.44  22.748 3.9059 45.85  23.335 3.8088 44.72  23.734 3.7457 63.04  24.438 3.6394 21.10  28.915 3.0853 23.42  29.234 3.0524 23.36______________________________________</pre>
    
    <p>Further, the present invention is directed to crystalline Form I atorvastatin and hydrates thereof characterized by the following solid-state <sup>13</sup> C nuclear magnetic resonance spectrum wherein chemical shift is expressed in parts per million measured on a Bruker AX-250 spectrometer:</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">______________________________________Assignment  (7 kHz) Chemical Shift______________________________________C12 or C25            182.8  C12 or C25 178.4  C16 166.7 (broad)   and 159.3  Aromatic Carbons  C2-C5, C13-C18, C19-C24, C27-C32 137.0   134.9   131.1   129.5   127.6   123.5   120.9   118.2   113.8  C8, C10  73.1    70.5    68.1    64.9  Methylene Carbons  C6, C7, C9, C11  47.4    41.9    40.2  C33  26.4    25.2  C34  21.3______________________________________</pre>
    
    <p>In a preferred embodiment of the first aspect of the invention, crystalline Form I atorvastatin is a trihydrate.</p>
    <p>In a second aspect, the present invention is directed to crystalline Form II atorvastatin and hydrates thereof characterized by the following X-ray powder diffraction pattern expressed in terms of the 2θ, d-spacings, and relative intensities with a relative intensity of &gt;20% measured after 2 minutes of grinding and measured on a Siemens D-500 diffractometer with CuK.sub.α  radiation:</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">______________________________________                      Relative    Intensity    (&gt;20%) Ground  2θ d 2 Minutes______________________________________5.582               15.8180    42.00  7.384  11.9620 38.63  8.533  10.3534 100.00  9.040   9.7741 92.06  12.440 (broad)  7.1094 30.69  15.771 (broad)  5.6146 38.78  17.120-17.360 (broad) 5.1750-5.1040 63.66-55.11  19.490   4.5507 56.64  20.502   4.3283 67.20  22.706-23.159 (broad) 3.9129-3.8375 49.20-48.00  25.697 (broad)  3.4639 38.93  29.504   3.0250 37.86______________________________________</pre>
    
    <p>Further, the second aspect of the present invention is directed to crystalline Form II atorvastatin and hydrates thereof characterized by the following solid-state <sup>13</sup> C nuclear magnetic resonance spectrum wherein chemical shift is expressed in parts per million measured on a Bruker AX-250 spectrometer:</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">______________________________________                 Chemical  Assignment Shift______________________________________Spinning Side Band      209.1  Spinning Side Band 206.8  C12 or C25 181 (broad)  C12 or C25 163 (broad)  C16 161 (broad)  Aromatic Carbons  C2-C5, C13-C18, C19-C24, C27-C32 140.5   134.8   133.3   129.0   122.9   121.4   120.3   119.0   117.1   115.7   114.7  C8, C10 70.6   69.0   68.0   67.3  Spinning Side Band 49.4  Spinning Side Band 48.9  Methylene Carbons  C6, C7, C9, C11 43.4   42.3   41.7   40.2  C33 27.5  C34 22.8 (broad)______________________________________</pre>
    
    <p>In a third aspect, the present invention is directed to crystalline Form IV atorvastatin and hydrates thereof characterized by the following X-ray powder diffraction pattern expressed in terms of the 2θ, d-spacings, and relative intensities with a relative intensity of &gt;15% measured on a Siemens D-500 diffractometer with CuK.sub.α  radiation:</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">______________________________________                  Relative    Intensity  2θ  d (&gt;15%)______________________________________ 4.889        18.605   38.45   5.424 16.2804  20.12   5.940 14.8660  17.29   7.997 11.0465  100.00   9.680 9.1295 67.31  10.416 8.4859 20.00  12.355 7.1584 19.15  17.662 5.0175 18.57  18.367 4.8265 23.50  19.200 4.6189 18.14  19.569 4.5327 54.79  21.723 4.0879 17.99  23.021 3.8602 28.89  23.651 3.7587 33.39  24.143 3.6832 17.23______________________________________</pre>
    
    <p>Further, the fourth aspect of the present invention is directed to Form IV atorvastatin and hydrates thereof characterized by the following solid-state <sup>13</sup> C nuclear magnetic resonance spectrum wherein chemical shift is expressed as parts per million measured on a Bruker AX-250 spectrometer:</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">______________________________________Assignment            Chemical Shift______________________________________C12 or C25            186.4   184.9  C12 or C25 181.4   179.3  C16 166.1 (broad)   and   159.0 (broad)  Aromatic Carbons  C2-C5, C13-C18, C19-C24, C27-C32 138.1 (broad)   134.7   129.2   127.1   122.7   119.8   115.7  C8, C10 71.5   67.9   66.3   63.5  Methylene Carbons  C6, C7, C9, C11 46.1   43.4   42.1   40.0  C33 25.9  C34 20.3   19.4   17.9______________________________________</pre>
    
    <p>As inhibitors of HMG-CoA, the novel crystalline forms of atorvastatin are useful hypolipidemic and hypocholesterolemic agents.</p>
    <p>A still further embodiment of the present invention is a pharmaceutical composition for administering an effective amount of crystalline Form I, Form II, or Form IV atorvastatin in unit dosage form in the treatment methods mentioned above. Finally, the present invention is directed to methods for production of Form I, Form II, or Form IV atorvastatin.</p>
    <heading>BRIEF DESCRIPTION OF THE DRAWINGS</heading> <p>The invention is further described by the following nonlimiting examples which refer to the accompanying FIGS. 1 to 6, short particulars of which are given below.</p>
    <p>FIG. 1</p>
    <p>Diffractogram of Form I atorvastatin ground for 2 minutes (Y-axis=0 to maximum intensity of 3767.50 counts per second (cps))</p>
    <p>FIG. 2</p>
    <p>Diffractogram of Form II atorvastatin ground for 2 minutes (Y-axis=0 to maximum intensity of 1500 cps)</p>
    <p>FIG. 3</p>
    <p>Diffractogram of Form IV atorvastatin (Y-axis=0 to maximum intensity of 8212.5 cps).</p>
    <p>FIG. 4</p>
    <p>Solid-state <sup>13</sup> C nuclear magnetic resonance spectrum with spinning side bands identified by an asterisk of Form I atorvastatin.</p>
    <p>FIG. 5</p>
    <p>Solid-state <sup>13</sup> C nuclear magnetic resonance spectrum with spinning side bands identified by an asterisk of Form II atorvastatin.</p>
    <p>FIG. 6</p>
    <p>Solid-state <sup>13</sup> C nuclear magnetic resonance spectrum with spinning side bands identified by an asterisk of Form IV atorvastatin.</p>
    <heading>DETAILED DESCRIPTION OF THE INVENTION</heading> <p>Crystalline Form I, Form II, or Form IV atorvastatin may be characterized by their X-ray powder diffraction patterns and/or by their solid state nuclear magnetic resonance spectra (NMR).</p>
    <heading>X-RAY POWDER DIFFRACTION</heading> <p>Forms I, II, and IV Atorvastatin</p>
    <p>Forms I, II, or Form IV atorvastatin were characterized by their X-ray powder diffraction pattern. Thus, the X-ray diffraction patterns of Forms I, II, and Form IV atorvastatin were measured on a Siemens D-500 diffractometer with CuK.sub.α  radiation.</p>
    <p>Equipment</p>
    <p>Siemens D-500 Diffractometer-Kristalloflex with an IBM-compatible interface, software=DIFFRAC AT (SOCABIM 1986, 1992). CuK.sub.α radiation (20 mA, 40 kV, λ=1.5406 Å) Slits I and II at 1°) electronically filtered by the Kevex Psi Peltier Cooled Silicon [Si(Li)]Detector (Slits: III at 1° and IV at 0.15°).</p>
    <p>Methodology</p>
    <p>The silicon standard is run each day to check the X-ray tube alignment.</p>
    <p>Continuous θ/2θ coupled scan: 4.00° to 40.00° in 2θ, scan rate of 6°/min: 0.4 sec/0.04° step.</p>
    <p>Sample tapped out of vial and pressed onto zero-background quartz in aluminum holder. Sample width 13-15 mm.</p>
    <p>Samples are stored and run at room temperature.</p>
    <p>Grinding/Sieving</p>
    <p>Grinding is used to minimize intensity variations for the diffractogram disclosed herein. However, if grinding significantly altered the diffractogram or increased the amorphous content of the sample, then the diffractogram of the unground sample was used. Grinding was done in a small agate mortar and pestle. The mortar was held during the grinding and light pressure was applied to the pestle.</p>
    <p>Ground Form II atorvastatin was sieved through a 230 mesh screen before analysis by x-ray diffraction.</p>
    <p>Table 1 lists the 2θ, d-spacings, and relative intensities of all lines in the unground sample with a relative intensity of &gt;20% for crystalline Form I atorvastatin. Table 1 also lists the relative intensities of the same lines in a diffractogram measured after 2 minutes of grinding. The intensities of the sample ground for 2 minutes are more representative of the diffraction pattern without preferred orientation. It should also be noted that the computer-generated, unrounded numbers are listed in this table.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 1______________________________________Intensities and Peak Locations of  all Diffraction Lines With Relative  Intensity Greater Than 20% for  Form I Atorvastatin                     Relative                            Relative    Intensity Intensity    (&gt;20%) (&gt;20%)*    No Ground  2θ d Grinding 2 Minutes______________________________________ 9.150   9.6565       37.42    42.60   9.470 9.3311 46.81 41.94  10.266 8.6098 75.61 55.67  10.560 8.3705 24.03 29.33  11.853 7.4601 55.16 41.74  12.195 7.2518 20.03 24.62  17.075 5.1887 25.95 60.12  19.485 4.5520 89.93 73.59  21.626 4.1059 100.00  100.00  21.960 4.0442 58.64 49.44  22.748 3.9059 36.95 45.85  23.335 3.8088 31.76 44.72  23.734 3.7457 87.55 63.04  24.438 3.6394 23.14 21.10  28.915 3.0853 21.59 23.42  29.234 3.0524 20.45 23.36______________________________________ *The second relative intensity column gives the relative intensities of the diffraction lines on the original diffractogram after 2 minutes of grinding.</pre>
    
    <p>Table 2 lists the 2θ, d-spacings, and relative intensities of all lines in the ground/sieved sample with a relative intensity of &gt;20% for crystalline Form II atorvastatin. It should also be noted that the computer-generated unrounded numbers are listed in this table.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 2______________________________________Intensities and Peak Locations of All  Diffraction Lines With Relative Intensity  Greater Than 20% for Form II Atorvastatin                           Relative    Intensity  2θ d (&gt;20%)______________________________________5.582                15.8180    42.00  7.384  11.9620  38.63  8.533  10.3534  100.00  9.040  9.7741 92.06  12.440 (broad) 7.1094 30.69  15.771 (broad) 5.6146 38.78  17.120-17.360 (broad) 5.1750-5.1040 63.66-55.11  19.490  4.5507 56.64  20.502  4.3283 67.20  22.706-23.159 (broad) 3.9129-3.8375 49.20-48.00  25.697 (broad) 3.4639 38.93  29.504  3.0250 37.86______________________________________</pre>
    
    <p>Table 3 lists the 2θ, d-spacings, and relative intensities of all lines in the unground sample with a relative intensity of &gt;15% for crystalline Form IV atorvastatin. It should also be noted that the computer-generated unrounded numbers are listed in this table.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 3______________________________________Intensities and Peak Locations of All  Diffraction Lines With Relative Intensity  Greater Than 15% for Form IV Atorvastatin                       Relative    Intensity  2θ d (&gt;15%)______________________________________ 4.889         18.605   38.45   5.424 16.2804  20.12   5.940 14.8660  17.29   7.997 11.0465  100.00   9.680 9.1295 67.31  10.416 8.4859 20.00  12.355 7.1584 19.15  17.662 5.0175 18.57  18.367 4.8265 23.50  19.200 4.6189 18.14  19.569 4.5327 54.79  21.723 4.0879 17.99  23.021 3.8602 28.89  23.651 3.7587 33.39  24.143 3.6832 17.23______________________________________</pre>
    
    <heading>SOLID STATE NUCLEAR MAGNETIC RESONANCE (NMR)</heading> <p>Methodology</p>
    <p>All solid-state <sup>13</sup> C NMR measurements were made with a Bruker AX-250, 250 MHz NMR spectrometer. High resolution spectra were obtained using high-power proton decoupling and cross-polarization (CP) with magic-angle spinning (MAS) at approximately 5 kHz. The magic-angle was adjusted using the Br signal of KBr by detecting the side bands as described by Frye and Maciel (Frye J. S. and Maciel G. E., J. Mag. Res., 1982;48:125). Approximately 300 to 450 mg of sample packed into a canister-design rotor was used for each experiment. Chemical shifts were referenced to external tetrakis (trimethylsilyl)silane (methyl signal at 3.50 ppm) (Muntean J. V. and Stock L. M., J. Mag. Res., 1988;76:54).</p>
    <p>Table 4 shows the solid-state NMR spectrum for crystalline Form I atorvastatin.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">                                  TABLE 4__________________________________________________________________________1  STR1##   - Carbon Atom Assignment and Chemical  Shift for Form I AtorvastatinAssignment       Chemical  (7 kHz) Shift__________________________________________________________________________C12 or C25            182.8  C12 or C25 178.4  C16 166.7 (broad)   and 159.3  Aromatic Carbons 137.0  C2-C5, C13-C18, C19-C24, C27-C32 134.9   131.1   129.5   127.6   123.5   120.9   118.2   113.8  C8, C10 73.1   70.5   68.1   64.9  Methylene Carbons 47.4  C6, C7, C9, C11 41.9   40.2  C33 26.4   25.2  C34 21.3__________________________________________________________________________</pre>
    
    <p>Table 5 shows the solid-state NMR spectrum for crystalline Form II atorvastatin.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 5______________________________________Carbon Atom Assignment and Chemical  Shift for Form II AtorvastatinAssigmnent           Chemical Shift______________________________________Spinning Side Band      209.1  Spinning Side Band 206.8  C12 or C25 181 (broad)  C12 or C25 163 (broad)  C16 161 (broad)  Aromatic Carbons  C2-C5, C13-C18, C19-C24, C27-C32 140.5   134.8   133.3   129.0   122.9   121.4   120.3   119.0   117.1   115.7   114.7   70.6   69.0  C8, C10 68.0   67.3  Spinning Side Band 49.4  Spinning Side Band 48.9  Methylene Carbons  C6, C7, C9, C11 43.4   42.3   41.7   40.2  C33 27.5  C34 22.8 (broad)______________________________________</pre>
    
    <p>Table 6 shows the solid-state NMR spectrum for crystalline Form IV atorvastatin.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 6______________________________________Carbon Atom Assignment and Chemical Shift  for Form IV Atorvastatin    Assignment           Chemical Shift______________________________________C12 or C25           186.4   184.9  C12 or C25 181.4   179.3  C16 166.1 (broad) and   159.0 (broad)  Aromatic Carbons  C2-C5, C13-C18, C19-C24, C27-C32 138.1 (broad)   134.7   129.2   127.1   122.7   119.8   115.7  C8, C10 71.5   67.9   66.3   63.5  Methylene Carbons  C6, C7, C9, C11 46.1   43.4   42.1   40.0  C33 25.9  C34 20.3   19.4   17.9______________________________________</pre>
    
    <p>Crystalline Form I, Form II, and Form IV atorvastatin of the present invention may exist in anhydrous forms as well as hydrated forms. In general, the hydrated forms, are equivalent to unhydrated forms and are intended to be encompassed within the scope of the present invention. Crystalline Form I atorvastatin contains about 1 to 8 mol of water. Preferably, Form I atorvastatin contains 3 mol of water.</p>
    <p>The present invention provides a process for the preparation of crystalline Form I atorvastatin which comprises crystallizing atorvastatin from a solution in solvents under conditions which yield crystalline Form I atorvastatin.</p>
    <p>The precise conditions under which crystalline Form I atorvastatin is formed may be empirically determined and it is only possible to give a number of methods which have been found to be suitable in practice.</p>
    <p>Thus, for example, crystalline Form I atorvastatin may be prepared by crystallization under controlled conditions. In particular, it can be prepared either from an aqueous solution of the corresponding basic salt such as, an alkali metal salt, for example, lithium, potassium, sodium, and the like; ammonia or an amine salt; preferably, the sodium salt by addition of a calcium salt, such as, for example, calcium acetate and the like, or by suspending amorphous atorvastatin in water. In general, the use of a hydroxylic co-solvent such as, for example, a lower alkanol, for example methanol and the like, is preferred.</p>
    <p>When the starting material for the preparation of the desired crystalline Form I atorvastatin is a solution of the corresponding sodium salt, one preferred preparation involves treating a solution of the sodium salt in water containing not less than about 5% v/v methanol, preferably about 5% to 33% v/v methanol, particularly preferred about 10% to 15% v/v methanol, with an aqueous solution of calcium acetate, preferably at an elevated temperature at up to about 70° C. such as, for example, about 45-60° C., particularly preferred about 47-52° C. It is preferable to use calcium acetate and, in general, 1 mole of calcium acetate to 2 moles of the sodium salt of atorvastatin. Under these conditions, calcium salt formation as well as crystallization should preferably be carried out at an elevated temperature, for example within the above-mentioned temperature ranges. It has been found that it may be advantageous to include in the starting solution a small amount of methyl tert-butyl ether (MTBE) such as, for example, about 7% w/w. It has frequently been found desirable to add "seeds" of crystalline Form I atorvastatin to the crystallization solution in order to consistently produce crystalline Form I atorvastatin.</p>
    <p>When the starting material is amorphous atorvastatin or a combination of amorphous and crystalline Form I Atorvastatin, the desired crystalline Form I atorvastatin may be obtained by suspending the solid in water containing up to about 40% v/v, such as, for example, about 0% to 20% v/v, particularly preferred about 5% to 15% v/v co-solvent such as, for example, methanol, ethanol, 2-propanol, acetone, and the like until conversion to the required form is complete, followed by filtration. It has frequently been found desirable to add "seeds" of crystalline Form I atorvastatin to the suspension in order to ensure complete conversion to crystalline Form I atorvastatin. Alternatively, a water-wet cake consisting principally of amorphous atorvastatin can be heated at elevated temperatures such as, for example, up to about 75° C., particularly preferred about 65-70° C., until a significant amount of crystalline Form I atorvastatin is present, whereupon the amorphous/crystalline Form I mixture can be slurried as described above.</p>
    <p>Crystalline Form I atorvastatin is significantly easier to isolate than amorphous atorvastatin and can be filtered from the crystallization medium after cooling, and washed and dried. For example, filtration of a 50 mL slurry of crystalline Form I atorvastatin was complete within 10 seconds. A similarly sized sample of amorphous atorvastatin took more than an hour to filter.</p>
    <p>The present invention also provides a process for the preparation of crystalline Form II atorvastatin which comprises suspending atorvastatin in solvents under conditions which yield crystalline Form II atorvastatin.</p>
    <p>The precise conditions under which Form II of crystalline atorvastatin is formed may be empirically determined and it is only possible to give a method which has been found to be suitable in practice.</p>
    <p>Thus, for example, when the starting material is amorphous, a combination of amorphous and Form I, or crystalline Form I atorvastatin, the desired Form II of crystalline atorvastatin may be obtained by suspending the solid in methanol containing about 40% to about 50% water until conversion to the required form is complete, followed by filtration.</p>
    <p>The present invention also provides a process for the preparation of crystalline Form IV atorvastatin which comprises crystallizing atorvastatin from a solution thereof in solvents under conditions which yield crystalline Form IV atorvastatin.</p>
    <p>The precise conditions under which Form IV of crystalline atorvastatin is formed may be empirically determined and it is only possible to give a method which has been found to be suitable in practice.</p>
    <p>Thus, for example, when the starting material is Form I of crystalline atorvastatin, the desired Form IV of crystalline atorvastatin may be obtained by dissolving the solid in methanol whereupon crystalline Form IV precipitates.</p>
    <p>The compounds of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compounds of the present invention can be administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active component, either compounds or a corresponding pharmaceutically acceptable salt of a compound of the present invention.</p>
    <p>For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.</p>
    <p>In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.</p>
    <p>In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.</p>
    <p>The powders and tablets preferably contain from two or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component, with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.</p>
    <p>For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.</p>
    <p>Liquid form preparations include solutions, suspensions, retention enemas, and emulsions, for example water or water propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.</p>
    <p>Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents as desired.</p>
    <p>Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.</p>
    <p>Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.</p>
    <p>The pharmaceutical preparation is preferably in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.</p>
    <p>The quantity of active component in a unit dose preparation may be varied or adjusted from 0.5 mg to 100 mg, preferably 2.5 mg to 80 mg according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.</p>
    <p>In therapeutic use as hypolipidemic and/or hypocholesterolemic agents, the crystalline Forms I, II, and Form IV atorvastatin utilized in the pharmaceutical method of this invention are administered at the initial dosage of about 2.5 mg to about 80 mg daily. A daily dose range of about 2.5 mg to about 20 mg is preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstance is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.</p>
    <p>The following nonlimiting examples illustrate the inventors' preferred methods for preparing the compounds of the invention.</p>
    <heading>EXAMPLE 1</heading> <heading>[R-(R*,R*)]-2-(4-Fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (Form I Atorvastatin)</heading> <p>Method A</p>
    <p>A mixture of (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide (atorvastatin lactone) (U.S. Pat. No. 5,273,995) (75 kg), methyl tertiary-butyl ether (MTBE) (308 kg), methanol (190 L) is reacted with an aqueous solution of sodium hydroxide (5.72 kg in 950 L) at 48-58° C. for 40 to 60 minutes to form the ring-opened sodium salt. After cooling to 25-35° C., the organic layer is discarded, and the aqueous layer is again extracted with MTBE (230 kg). The organic layer is discarded, and the MTBE saturated aqueous solution of the sodium salt is heated to 47-52° C. To this solution is added a solution of calcium acetate hemihydrate (11.94 kg) dissolved in water (410 L), over at least 30 minutes. The mixture is seeded with a slurry of crystalline Form I atorvastatin (1.1 kg in 11 L water and 5 L methanol) shortly after addition of the calcium acetate solution. The mixture is then heated to 51-57° C. for at least 10 minutes and then cooled to 15-40° C. The mixture is filtered, washed with a solution of water (300 L) and methanol (150 L) followed by water (450 L). The solid is dried at 60-70° C. under vacuum for 3 to 4 days to give crystalline Form I atorvastatin (72.2 kg).</p>
    <p>Method B</p>
    <p>Amorphous atorvastatin (9 g) and crystalline Form I atorvastatin (1 g) are stirred at about 40° C. in a mixture of water (170 mL) and methanol (30 mL) for a total of 17 hours. The mixture is filtered, rinsed with water, and dried at 70° C. under reduced pressure to give crystalline Form I atorvastatin (9.7 g).</p>
    <heading>EXAMPLE 2</heading> <heading>[R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (Form II Atorvastatin)</heading> <p>A mixture of amorphous and crystalline Form I atorvastatin (100 g) was suspended in a mixture of methanol (1200 mL) and water (800 mL) and stirred for 3 days. The material was filtered, dried at 70° C. under reduced pressure to give crystalline Form II atorvastatin.</p>
    <heading>EXAMPLE 3</heading> <heading>[R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (Form IV Atorvastatin)</heading> <p>A mixture of (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide (atorvastatin lactone) (U.S. Pat. No. 5,273,995) (12 kg), MTBE (50 kg), methanol (30 L) is reacted with an aqueous solution of sodium hydroxide (1.83 kg in 150 L) at 50-55° C. for 30-45 minutes to form the ring-opened sodium salt. After cooling to 20-25° C., the organic layer is discarded and the aqueous layer is again extracted with MTBE (37 kg). The organic layer is discarded and the aqueous solution of the sodium salt is heated to 70-80° C. and the residual MTBE is removed by distillation. The solution is then cooled to 60-70° C. To this solution is added a solution of calcium acetate hemihydrate (1.91 kg) dissolved in water/methanol (72 L water+16 L methanol). The mixture is seeded with crystalline Form I atorvastatin (180 g) shortly after addition of the calcium acetate solution. The mixture is heated at 65-75° C. for at least 5 minutes and then cooled to 50-55° C. The mixture is filtered and slurried in methanol (about 200 L) at 55-65° C. and then cooled to 25-30° C. and filtered. The solid is dried at 66-70° C. under vacuum to give Form IV of crystalline atorvastatin (about 3 kg isolated).</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5316765">US5316765</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 19, 1991</td><td class="patent-data-table-td patent-date-value">May 31, 1994</td><td class="patent-data-table-td ">Karl Folkers Foundation For Biomedical And Clinical Research</td><td class="patent-data-table-td ">Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0409281A1?cl=en">EP0409281A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 20, 1990</td><td class="patent-data-table-td patent-date-value">Jan 23, 1991</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">(R-(R*R*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl-3-phenyl-4((phenylamino)-carbonyl)-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1994016693A1?cl=en">WO1994016693A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 20, 1993</td><td class="patent-data-table-td patent-date-value">Aug 4, 1994</td><td class="patent-data-table-td ">Warner Lambert Co</td><td class="patent-data-table-td ">Stable oral ci-981 formulation and process of preparing same</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Bocan, Thomas et al., Antiaherosclerotic activity of inhibitors of 3 hydroxy 3 methylgutaryl coenzyme A reductase, Atherosclerosis, 111, 127 142, Dec. 1994.</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bocan, Thomas et al., Antiaherosclerotic activity of inhibitors of 3-hydroxy-3-methylgutaryl coenzyme A reductase, Atherosclerosis, 111, 127-142, Dec. 1994.</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Pharmaceutical Research , vol. 10, No. 10, 1993, pp. 1461 1465, Kearney, et al.</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pharmaceutical Research, vol. 10, No. 10, 1993, pp. 1461-1465, Kearney, et al.</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Tetrahedron Letters , vol. 33, No. 17, 1992, pp. 2283 2284, Baumann, et al.</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Tetrahedron Letters, vol. 33, No. 17, 1992, pp. 2283-2284, Baumann, et al.</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6087511">US6087511</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 16, 1996</td><td class="patent-data-table-td patent-date-value">Jul 11, 2000</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6274740">US6274740</a></td><td class="patent-data-table-td patent-date-value">Sep 7, 2000</td><td class="patent-data-table-td patent-date-value">Aug 14, 2001</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethy)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6476235">US6476235</a></td><td class="patent-data-table-td patent-date-value">Dec 17, 2001</td><td class="patent-data-table-td patent-date-value">Nov 5, 2002</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6545153">US6545153</a></td><td class="patent-data-table-td patent-date-value">Jul 18, 2002</td><td class="patent-data-table-td patent-date-value">Apr 8, 2003</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Anticholesterol agents; antilipemic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6600051">US6600051</a></td><td class="patent-data-table-td patent-date-value">Jun 14, 2002</td><td class="patent-data-table-td patent-date-value">Jul 29, 2003</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6605636">US6605636</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 5, 2001</td><td class="patent-data-table-td patent-date-value">Aug 12, 2003</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Atorvastatin hemi-calcium form VII</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6605728">US6605728</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 14, 2002</td><td class="patent-data-table-td patent-date-value">Aug 12, 2003</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Starting from atorvastatin lactone, where continuous agitation at a very low speed provides optimum drying conditions for avoiding clod formation and particle attrition</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6605729">US6605729</a></td><td class="patent-data-table-td patent-date-value">Jun 28, 2002</td><td class="patent-data-table-td patent-date-value">Aug 12, 2003</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6730797">US6730797</a></td><td class="patent-data-table-td patent-date-value">Aug 8, 2003</td><td class="patent-data-table-td patent-date-value">May 4, 2004</td><td class="patent-data-table-td ">Pfizer Science And Technology Ireland Limited</td><td class="patent-data-table-td ">Process for producing crystalline atorvastatin calcium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6750353">US6750353</a></td><td class="patent-data-table-td patent-date-value">Dec 18, 2002</td><td class="patent-data-table-td patent-date-value">Jun 15, 2004</td><td class="patent-data-table-td ">Lek Pharmaceutical &amp; Chemical Co. D.D.</td><td class="patent-data-table-td ">Preparation of pharmaceutically acceptable atorvastatin salts in non-crystalline form</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6777552">US6777552</a></td><td class="patent-data-table-td patent-date-value">Aug 16, 2002</td><td class="patent-data-table-td patent-date-value">Aug 17, 2004</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries, Ltd.</td><td class="patent-data-table-td ">From an ester derivative or protected ester derivative of the statin by using calcium hydroxide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6777560">US6777560</a></td><td class="patent-data-table-td patent-date-value">Aug 6, 2003</td><td class="patent-data-table-td patent-date-value">Aug 17, 2004</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for preparing 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6933393">US6933393</a></td><td class="patent-data-table-td patent-date-value">Jan 21, 2003</td><td class="patent-data-table-td patent-date-value">Aug 23, 2005</td><td class="patent-data-table-td ">Warner-Lambert Company Llc</td><td class="patent-data-table-td ">Reacting methyl cyanoacetate with morphiline to form 3-morpholin-4-yl-3-oxo- propionitrile; forming salt; reacting with phenylacetic acid and 2-(2-(4-fluorophenyl)-2-oxo-1-phenyl-ethyl)-4-</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6992194">US6992194</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 28, 2004</td><td class="patent-data-table-td patent-date-value">Jan 31, 2006</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries, Ltd.</td><td class="patent-data-table-td ">suspending crystal strutured or amorphous lipitor in diluents comprising alcohols and/or water mixtures to cause conversion, then separating the diluents; monodispersity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7041835">US7041835</a></td><td class="patent-data-table-td patent-date-value">Jan 23, 2004</td><td class="patent-data-table-td patent-date-value">May 9, 2006</td><td class="patent-data-table-td ">Dor Pharmaceutical, Inc.</td><td class="patent-data-table-td ">(−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7074940">US7074940</a></td><td class="patent-data-table-td patent-date-value">Oct 3, 2003</td><td class="patent-data-table-td patent-date-value">Jul 11, 2006</td><td class="patent-data-table-td ">Lek Pharmaceutical &amp; Chemical Co. D.D.</td><td class="patent-data-table-td ">Preparation of pharmaceutically acceptable atorvastatin salts in non-crystalline forms</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7081471">US7081471</a></td><td class="patent-data-table-td patent-date-value">Jan 23, 2004</td><td class="patent-data-table-td patent-date-value">Jul 25, 2006</td><td class="patent-data-table-td ">Dov Pharmaceutical, Inc.</td><td class="patent-data-table-td ">(-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7084282">US7084282</a></td><td class="patent-data-table-td patent-date-value">Jun 8, 2004</td><td class="patent-data-table-td patent-date-value">Aug 1, 2006</td><td class="patent-data-table-td ">Warner-Lambert Company Llc</td><td class="patent-data-table-td ">Process for preparing 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7098230">US7098230</a></td><td class="patent-data-table-td patent-date-value">Jan 23, 2004</td><td class="patent-data-table-td patent-date-value">Aug 29, 2006</td><td class="patent-data-table-td ">Dov Pharmaceutical, Inc.</td><td class="patent-data-table-td ">(-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7122681">US7122681</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 19, 2003</td><td class="patent-data-table-td patent-date-value">Oct 17, 2006</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries, Ltd.</td><td class="patent-data-table-td ">Displacement of solvent by vapor diffusion of water</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7144915">US7144915</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 6, 2003</td><td class="patent-data-table-td patent-date-value">Dec 5, 2006</td><td class="patent-data-table-td ">Warner-Lambert Company, Llc</td><td class="patent-data-table-td ">Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7144916">US7144916</a></td><td class="patent-data-table-td patent-date-value">Nov 19, 2004</td><td class="patent-data-table-td patent-date-value">Dec 5, 2006</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7151183">US7151183</a></td><td class="patent-data-table-td patent-date-value">Jul 29, 2005</td><td class="patent-data-table-td patent-date-value">Dec 19, 2006</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Processes for preparing amorphous atorvastatin hemi-calcium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7161012">US7161012</a></td><td class="patent-data-table-td patent-date-value">Jul 29, 2005</td><td class="patent-data-table-td patent-date-value">Jan 9, 2007</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Processes for preparing amorphous atorvastatin hemi-calcium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7183408">US7183408</a></td><td class="patent-data-table-td patent-date-value">Apr 19, 2005</td><td class="patent-data-table-td patent-date-value">Feb 27, 2007</td><td class="patent-data-table-td ">Warner-Lambert Company, Llc</td><td class="patent-data-table-td ">calcium atorvastatin (Lipitor) intermediate; from claimed intermediate 5-(4-fluorophenyl)-2-isopropyl-1-(3-morpholin-4-yl-3-oxo-propyl)-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide; via diol esters from the 1,3,5-tricarbonyl precursors in a stereoselective ruthenium-catalyzed hydrogenation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7189861">US7189861</a></td><td class="patent-data-table-td patent-date-value">Jul 29, 2005</td><td class="patent-data-table-td patent-date-value">Mar 13, 2007</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries, Ltd.</td><td class="patent-data-table-td ">Ball milling any crystalline form of atorvastatin hemi-calcium to obtain a polymorphic crystal structure with small particle size distribution; monodispersity; improved physical properties of filtration/drying characteristics, flowability, vapor impermeability, solubility; drug-releasing design</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7208608">US7208608</a></td><td class="patent-data-table-td patent-date-value">Jan 30, 2003</td><td class="patent-data-table-td patent-date-value">Apr 24, 2007</td><td class="patent-data-table-td ">Zentiva A. S.</td><td class="patent-data-table-td ">Conversion of (3R,5R) 7-[3-phenyl-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid or its salt containing alkali metal or ammonium cation, by treatment of the calcium salt to the hemi-calcium salt, followed by precipitation with C5 C12 hydrocarbon or dialkyl ether</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7256212">US7256212</a></td><td class="patent-data-table-td patent-date-value">Jul 29, 2005</td><td class="patent-data-table-td patent-date-value">Aug 14, 2007</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7276536">US7276536</a></td><td class="patent-data-table-td patent-date-value">Mar 17, 2004</td><td class="patent-data-table-td patent-date-value">Oct 2, 2007</td><td class="patent-data-table-td ">Japan Tobacco Inc.</td><td class="patent-data-table-td ">By administering with food; drug is dalcetrapib; use in treatment of cardiovascular disease, coronary heart disease, coronary artery disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7323490">US7323490</a></td><td class="patent-data-table-td patent-date-value">May 18, 2004</td><td class="patent-data-table-td patent-date-value">Jan 29, 2008</td><td class="patent-data-table-td ">Ambit Biosciences Corporation</td><td class="patent-data-table-td ">Pyrrole compounds and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7342120">US7342120</a></td><td class="patent-data-table-td patent-date-value">Oct 24, 2005</td><td class="patent-data-table-td patent-date-value">Mar 11, 2008</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries, Ltd.</td><td class="patent-data-table-td ">Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7361771">US7361771</a></td><td class="patent-data-table-td patent-date-value">Oct 11, 2006</td><td class="patent-data-table-td patent-date-value">Apr 22, 2008</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7371855">US7371855</a></td><td class="patent-data-table-td patent-date-value">Oct 11, 2006</td><td class="patent-data-table-td patent-date-value">May 13, 2008</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7399773">US7399773</a></td><td class="patent-data-table-td patent-date-value">Oct 11, 2006</td><td class="patent-data-table-td patent-date-value">Jul 15, 2008</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Intermediates in the synthesis of atorvastatin calcium (Lipitor (reg)), 5-(4-fluorophenyl)-2-isopropyl-1-(4-(morpholinocarbonylmethylcarbonyl)-2-hydroxybutyl)-4-phenyl-3-(N-phenylcarbamoyl)-1H-pyrrole for example</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7411075">US7411075</a></td><td class="patent-data-table-td patent-date-value">Nov 16, 2000</td><td class="patent-data-table-td patent-date-value">Aug 12, 2008</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Polymorphic form of atorvastatin calcium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7446121">US7446121</a></td><td class="patent-data-table-td patent-date-value">Nov 18, 2005</td><td class="patent-data-table-td patent-date-value">Nov 4, 2008</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">Pyrazole-based HMG CoA reductase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7456297">US7456297</a></td><td class="patent-data-table-td patent-date-value">Jul 29, 2005</td><td class="patent-data-table-td patent-date-value">Nov 25, 2008</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">crystalline polymorphic dosage forms of anticholesterol agents; statins; small particle size distribution</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7468444">US7468444</a></td><td class="patent-data-table-td patent-date-value">Oct 24, 2005</td><td class="patent-data-table-td patent-date-value">Dec 23, 2008</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Crystalline polymorphic dosage forms of anticholesterol agents; statins; suspending atorvastatin hemi-calcium in water for 16 hours convert the atorvastatin hemi-calcium into Form I</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7488750">US7488750</a></td><td class="patent-data-table-td patent-date-value">Oct 24, 2005</td><td class="patent-data-table-td patent-date-value">Feb 10, 2009</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7501450">US7501450</a></td><td class="patent-data-table-td patent-date-value">Feb 19, 2003</td><td class="patent-data-table-td patent-date-value">Mar 10, 2009</td><td class="patent-data-table-td ">Teva Pharaceutical Industries Ltd.</td><td class="patent-data-table-td ">Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7534810">US7534810</a></td><td class="patent-data-table-td patent-date-value">Jul 9, 2008</td><td class="patent-data-table-td patent-date-value">May 19, 2009</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">Salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7538136">US7538136</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 19, 2001</td><td class="patent-data-table-td patent-date-value">May 26, 2009</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Crystalline forms of atorvastatin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7655692">US7655692</a></td><td class="patent-data-table-td patent-date-value">Apr 20, 2004</td><td class="patent-data-table-td patent-date-value">Feb 2, 2010</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">Dissolving atorvastatin in alcoholic solvent comprising methanol, ethanol, 1-propanol, or isopropanol; high speed evaporation by spray drying</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7674923">US7674923</a></td><td class="patent-data-table-td patent-date-value">Sep 28, 2005</td><td class="patent-data-table-td patent-date-value">Mar 9, 2010</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd</td><td class="patent-data-table-td ">atorvastatin calcium epoxide dihydroxy (AED) is described; AED can be used as a standard or marker in determining the amount of AED in a sample</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7732623">US7732623</a></td><td class="patent-data-table-td patent-date-value">Jul 11, 2008</td><td class="patent-data-table-td patent-date-value">Jun 8, 2010</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Form V, having improved water solubility over Form 1; formed by dissolving a metal, ammonium or alkylammonium salt of atorvastatin in a solvent, contacting with a calcium salt and isolating</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7790197">US7790197</a></td><td class="patent-data-table-td patent-date-value">Apr 20, 2004</td><td class="patent-data-table-td patent-date-value">Sep 7, 2010</td><td class="patent-data-table-td ">Warner-Lambert Company Llc</td><td class="patent-data-table-td ">Wet granulated particle form; compression; milling; benign prostate hyperplasia ; anticholesterol agents; antilipemic agents; Alzheimer&#39;s disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7834195">US7834195</a></td><td class="patent-data-table-td patent-date-value">Jun 14, 2007</td><td class="patent-data-table-td patent-date-value">Nov 16, 2010</td><td class="patent-data-table-td ">Apotex Pharmachem Inc.</td><td class="patent-data-table-td ">Adding atorvastatin calcium to propylene glycol/1,2-/; adding an organic cosolvent; optionally adding water; isolating and drying by filtration; crystallization; stability, moisturizer for drugs, cosmetics, foods, tobacco products, humectant food additives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7879585">US7879585</a></td><td class="patent-data-table-td patent-date-value">Oct 1, 2007</td><td class="patent-data-table-td patent-date-value">Feb 1, 2011</td><td class="patent-data-table-td ">Codexis, Inc.</td><td class="patent-data-table-td ">Ketoreductase enzymes and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7915302">US7915302</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 3, 2008</td><td class="patent-data-table-td patent-date-value">Mar 29, 2011</td><td class="patent-data-table-td ">Dong-A Pharm. Co., Ltd.</td><td class="patent-data-table-td ">Crystal forms of pyrrolylheptanoic acid derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7932403">US7932403</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 16, 2005</td><td class="patent-data-table-td patent-date-value">Apr 26, 2011</td><td class="patent-data-table-td ">Ratiopharm Gmbh</td><td class="patent-data-table-td ">Process for preparing pyrrole derivatives and intermediates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7939675">US7939675</a></td><td class="patent-data-table-td patent-date-value">Oct 12, 2005</td><td class="patent-data-table-td patent-date-value">May 10, 2011</td><td class="patent-data-table-td ">Pfizer, Inc.</td><td class="patent-data-table-td ">dissolving atorvastatin in a nonalcoholic solvent such as dimethylsulfoxide to form a solution; and lyophilizing the solution to form amorphous atorvastatin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8026376">US8026376</a></td><td class="patent-data-table-td patent-date-value">Jul 11, 2005</td><td class="patent-data-table-td patent-date-value">Sep 27, 2011</td><td class="patent-data-table-td ">Pfizer, Inc.</td><td class="patent-data-table-td ">Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoicacid calcium salt (2:1)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8080672">US8080672</a></td><td class="patent-data-table-td patent-date-value">Dec 13, 2006</td><td class="patent-data-table-td patent-date-value">Dec 20, 2011</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Crystal form of atorvastatin hemi-calcium and processes for preparation thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8084488">US8084488</a></td><td class="patent-data-table-td patent-date-value">Nov 9, 2006</td><td class="patent-data-table-td patent-date-value">Dec 27, 2011</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8115015">US8115015</a></td><td class="patent-data-table-td patent-date-value">Jan 26, 2009</td><td class="patent-data-table-td patent-date-value">Feb 14, 2012</td><td class="patent-data-table-td ">Cadila Healthcare Limited</td><td class="patent-data-table-td ">Process for the preparation of amorphous atorvastatin calcium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8138377">US8138377</a></td><td class="patent-data-table-td patent-date-value">Nov 6, 2007</td><td class="patent-data-table-td patent-date-value">Mar 20, 2012</td><td class="patent-data-table-td ">Dov Pharmaceutical, Inc.</td><td class="patent-data-table-td ">Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8158362">US8158362</a></td><td class="patent-data-table-td patent-date-value">Nov 9, 2005</td><td class="patent-data-table-td patent-date-value">Apr 17, 2012</td><td class="patent-data-table-td ">Decode Genetics Ehf.</td><td class="patent-data-table-td ">Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8188300">US8188300</a></td><td class="patent-data-table-td patent-date-value">Nov 15, 2010</td><td class="patent-data-table-td patent-date-value">May 29, 2012</td><td class="patent-data-table-td ">Apotex Pharmachem Inc.</td><td class="patent-data-table-td ">Atorvastatin calcium propylene glycol solvates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8236966">US8236966</a></td><td class="patent-data-table-td patent-date-value">Dec 13, 2010</td><td class="patent-data-table-td patent-date-value">Aug 7, 2012</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta, alpha-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8258315">US8258315</a></td><td class="patent-data-table-td patent-date-value">Apr 4, 2011</td><td class="patent-data-table-td patent-date-value">Sep 4, 2012</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">Process for forming amorphous atorvastatin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8273547">US8273547</a></td><td class="patent-data-table-td patent-date-value">Dec 23, 2010</td><td class="patent-data-table-td patent-date-value">Sep 25, 2012</td><td class="patent-data-table-td ">Codexis, Inc.</td><td class="patent-data-table-td ">Engineered ketoreductases and methods for producing stereoisomerically pure statins</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8383667">US8383667</a></td><td class="patent-data-table-td patent-date-value">Nov 14, 2011</td><td class="patent-data-table-td patent-date-value">Feb 26, 2013</td><td class="patent-data-table-td ">Warner Lambert Llc</td><td class="patent-data-table-td ">Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8404874">US8404874</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 28, 2011</td><td class="patent-data-table-td patent-date-value">Mar 26, 2013</td><td class="patent-data-table-td ">Wisconsin Alumni Research Foundation</td><td class="patent-data-table-td ">(20R,25S)-2-Methylene-19,26-Dinor-1α,25-Dihydroxyvitamin D3 in crystalline form</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8552207">US8552207</a></td><td class="patent-data-table-td patent-date-value">Jun 29, 2012</td><td class="patent-data-table-td patent-date-value">Oct 8, 2013</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8563750">US8563750</a></td><td class="patent-data-table-td patent-date-value">Aug 22, 2011</td><td class="patent-data-table-td patent-date-value">Oct 22, 2013</td><td class="patent-data-table-td ">Warner-Lambert Company Llc</td><td class="patent-data-table-td ">Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylmino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8617864">US8617864</a></td><td class="patent-data-table-td patent-date-value">Aug 9, 2012</td><td class="patent-data-table-td patent-date-value">Dec 31, 2013</td><td class="patent-data-table-td ">Codexis, Inc.</td><td class="patent-data-table-td ">Polynucleotides encoding ketoreductases for producing stereoisomerically pure statins and synthetic intermediates therefor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8648109">US8648109</a></td><td class="patent-data-table-td patent-date-value">Jan 22, 2013</td><td class="patent-data-table-td patent-date-value">Feb 11, 2014</td><td class="patent-data-table-td ">Warner-Lambert Company Llc</td><td class="patent-data-table-td ">Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8686163">US8686163</a></td><td class="patent-data-table-td patent-date-value">Jul 27, 2012</td><td class="patent-data-table-td patent-date-value">Apr 1, 2014</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">Process for forming amorphous atorvastatin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8697638">US8697638</a></td><td class="patent-data-table-td patent-date-value">Aug 26, 2008</td><td class="patent-data-table-td patent-date-value">Apr 15, 2014</td><td class="patent-data-table-td ">Cubist Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Methods for preparing purified lipopeptides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8765801">US8765801</a></td><td class="patent-data-table-td patent-date-value">Feb 3, 2012</td><td class="patent-data-table-td patent-date-value">Jul 1, 2014</td><td class="patent-data-table-td ">Euthymics Bioscience, Inc.</td><td class="patent-data-table-td ">Polymorphs of azabicyclohexane</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20090240064">US20090240064</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 20, 2007</td><td class="patent-data-table-td patent-date-value">Sep 24, 2009</td><td class="patent-data-table-td ">Venkata Panakala Rao Gogulapati</td><td class="patent-data-table-td ">Crystalline form of atorvastatin hemi-calcium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20100056605">US20100056605</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 6, 2009</td><td class="patent-data-table-td patent-date-value">Mar 4, 2010</td><td class="patent-data-table-td ">Lek Pharmaceuticals D.D.</td><td class="patent-data-table-td ">Oxidative degradation products of atorvastatin calcium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20120083614">US20120083614</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 28, 2011</td><td class="patent-data-table-td patent-date-value">Apr 5, 2012</td><td class="patent-data-table-td ">Wisconsin Alumni Research Foundation</td><td class="patent-data-table-td ">(20R,25S)-2-Methylene-19,26-Dinor-1alpha,25-Dihydroxyvitamin D3 in Crystalline Form</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20120165386">US20120165386</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 22, 2011</td><td class="patent-data-table-td patent-date-value">Jun 28, 2012</td><td class="patent-data-table-td ">Ranbaxy Laboratories Limited</td><td class="patent-data-table-td ">Stable oral pharmaceutial composition of atorvastatin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/USRE40667">USRE40667</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 16, 2007</td><td class="patent-data-table-td patent-date-value">Mar 17, 2009</td><td class="patent-data-table-td ">Warner-Lambert Company Llc</td><td class="patent-data-table-td ">[R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/CN100430405C?cl=en">CN100430405C</a></td><td class="patent-data-table-td patent-date-value">Aug 16, 2002</td><td class="patent-data-table-td patent-date-value">Nov 5, 2008</td><td class="patent-data-table-td ">特瓦制药工业有限公司</td><td class="patent-data-table-td ">Processes for preparing calcium salt forms of statins</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1535613A2?cl=en">EP1535613A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 16, 2000</td><td class="patent-data-table-td patent-date-value">Jun 1, 2005</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Polymorphic form of atorvastatin calcium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1584616A1?cl=en">EP1584616A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 18, 2000</td><td class="patent-data-table-td patent-date-value">Oct 12, 2005</td><td class="patent-data-table-td ">Pfizer Science and Technology Ireland Limited</td><td class="patent-data-table-td ">Industrial process for the production of crystalline atorvastatin trihydrate hemi calcium salt</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1734034A2?cl=en">EP1734034A2</a></td><td class="patent-data-table-td patent-date-value">Dec 27, 2001</td><td class="patent-data-table-td patent-date-value">Dec 20, 2006</td><td class="patent-data-table-td ">Warner-Lambert Company LLC</td><td class="patent-data-table-td ">Carboxylic acid salts of beta-alanine esters or -amides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1745020A2?cl=en">EP1745020A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 25, 2005</td><td class="patent-data-table-td patent-date-value">Jan 24, 2007</td><td class="patent-data-table-td ">Pfizer Products Incorporated</td><td class="patent-data-table-td ">Salt forms of atorvastatin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1977738A1?cl=en">EP1977738A1</a></td><td class="patent-data-table-td patent-date-value">Jun 1, 2004</td><td class="patent-data-table-td patent-date-value">Oct 8, 2008</td><td class="patent-data-table-td ">Warner-Lambert Company LLC</td><td class="patent-data-table-td ">Pharmaceutical compositions comprising atorvastatin manufactured without granulation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2192112A1?cl=en">EP2192112A1</a></td><td class="patent-data-table-td patent-date-value">Nov 29, 2001</td><td class="patent-data-table-td patent-date-value">Jun 2, 2010</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Process for preparing atorvastatin hemi-calcium Form I</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2192113A1?cl=en">EP2192113A1</a></td><td class="patent-data-table-td patent-date-value">Nov 29, 2001</td><td class="patent-data-table-td patent-date-value">Jun 2, 2010</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Novel crystal form XI of atorvastatin hemi-calcium and processes for its preparation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2194041A1?cl=en">EP2194041A1</a></td><td class="patent-data-table-td patent-date-value">Nov 29, 2001</td><td class="patent-data-table-td patent-date-value">Jun 9, 2010</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Novel crystal form IX of atorvastatin hemi-calcium and processes for its preparation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2206497A1?cl=en">EP2206497A1</a></td><td class="patent-data-table-td patent-date-value">Nov 16, 2000</td><td class="patent-data-table-td patent-date-value">Jul 14, 2010</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Polymorphic form of atorvastatin calcium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2292600A1?cl=en">EP2292600A1</a></td><td class="patent-data-table-td patent-date-value">Jan 7, 2002</td><td class="patent-data-table-td patent-date-value">Mar 9, 2011</td><td class="patent-data-table-td ">Dr. Reddy&#39;s Laboratories Ltd.</td><td class="patent-data-table-td ">Crystaline forms VI and VII of atorvastatin calcium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2420488A1?cl=en">EP2420488A1</a></td><td class="patent-data-table-td patent-date-value">Jan 28, 2011</td><td class="patent-data-table-td patent-date-value">Feb 22, 2012</td><td class="patent-data-table-td ">Kyongbo pharmaceutical, Co., Ltd</td><td class="patent-data-table-td ">Novel crystalline form of atorvastatin hemi-calcium salt, hydrate thereof, and method of producing the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2452683A2?cl=en">EP2452683A2</a></td><td class="patent-data-table-td patent-date-value">Jun 26, 2007</td><td class="patent-data-table-td patent-date-value">May 16, 2012</td><td class="patent-data-table-td ">Amgen Inc.</td><td class="patent-data-table-td ">Methods for treating atherosclerosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2489730A1?cl=en">EP2489730A1</a></td><td class="patent-data-table-td patent-date-value">Jul 25, 2008</td><td class="patent-data-table-td patent-date-value">Aug 22, 2012</td><td class="patent-data-table-td ">Amgen, Inc</td><td class="patent-data-table-td ">Modified lecithin-cholesterol acyltransferase enzymes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2489731A1?cl=en">EP2489731A1</a></td><td class="patent-data-table-td patent-date-value">Jul 25, 2008</td><td class="patent-data-table-td patent-date-value">Aug 22, 2012</td><td class="patent-data-table-td ">Amgen, Inc</td><td class="patent-data-table-td ">Modified lecithin-cholesterol acyltransferase enzymes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2522721A2?cl=en">EP2522721A2</a></td><td class="patent-data-table-td patent-date-value">Jul 25, 2008</td><td class="patent-data-table-td patent-date-value">Nov 14, 2012</td><td class="patent-data-table-td ">Amgen, Inc</td><td class="patent-data-table-td ">Modified lecithin-cholesterol acyltransferase enzymes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2540704A2?cl=en">EP2540704A2</a></td><td class="patent-data-table-td patent-date-value">Apr 25, 2005</td><td class="patent-data-table-td patent-date-value">Jan 2, 2013</td><td class="patent-data-table-td ">Pfizer Products Inc.</td><td class="patent-data-table-td ">Benethamine salt forms of atorvastatin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2001036384A1?cl=en">WO2001036384A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 16, 2000</td><td class="patent-data-table-td patent-date-value">May 25, 2001</td><td class="patent-data-table-td ">Ari Ayalon</td><td class="patent-data-table-td ">Polymorphic form of atorvastatin calcium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2001044180A1?cl=en">WO2001044180A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 18, 2000</td><td class="patent-data-table-td patent-date-value">Jun 21, 2001</td><td class="patent-data-table-td ">Warner Lambert Res &amp; Dev Ie</td><td class="patent-data-table-td ">A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2002043732A1?cl=en">WO2002043732A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 29, 2001</td><td class="patent-data-table-td patent-date-value">Jun 6, 2002</td><td class="patent-data-table-td ">Judith Aronhime</td><td class="patent-data-table-td ">Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2003011826A1?cl=en">WO2003011826A1</a></td><td class="patent-data-table-td patent-date-value">Jan 7, 2002</td><td class="patent-data-table-td patent-date-value">Feb 13, 2003</td><td class="patent-data-table-td ">Reddys Lab Ltd Dr</td><td class="patent-data-table-td ">Crystalline forms vi and vii of atorvastatin calcium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2003016317A1?cl=en">WO2003016317A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 16, 2002</td><td class="patent-data-table-td patent-date-value">Feb 27, 2003</td><td class="patent-data-table-td ">Rami Lidor-Hadas</td><td class="patent-data-table-td ">Processes for preparing calcium salt forms of statins</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004110409A1?cl=en">WO2004110409A1</a></td><td class="patent-data-table-td patent-date-value">Jun 1, 2004</td><td class="patent-data-table-td patent-date-value">Dec 23, 2004</td><td class="patent-data-table-td ">Alfred Berchielli</td><td class="patent-data-table-td ">Pharmaceutical compositions comprising atorvastatin manufactured without granulation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006037125A1?cl=en">WO2006037125A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 28, 2005</td><td class="patent-data-table-td patent-date-value">Apr 6, 2006</td><td class="patent-data-table-td ">Teva Pharma</td><td class="patent-data-table-td ">Process for preparing forms of atorvastatin calcium substantially free of impurities</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006045018A1?cl=en">WO2006045018A1</a></td><td class="patent-data-table-td patent-date-value">Oct 18, 2005</td><td class="patent-data-table-td patent-date-value">Apr 27, 2006</td><td class="patent-data-table-td ">Teva Pharma</td><td class="patent-data-table-td ">Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006048888A1?cl=en">WO2006048888A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 1, 2004</td><td class="patent-data-table-td patent-date-value">May 11, 2006</td><td class="patent-data-table-td ">Sreenivas Rao Bhatraju</td><td class="patent-data-table-td ">Novel process for the preparation of amorphous atorvastatin calcium salt</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006054308A2?cl=en">WO2006054308A2</a></td><td class="patent-data-table-td patent-date-value">Nov 22, 2005</td><td class="patent-data-table-td patent-date-value">May 26, 2006</td><td class="patent-data-table-td ">Dexcel Pharma Technologies Ltd</td><td class="patent-data-table-td ">Stable atorvastatin formulations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006059210A2?cl=en">WO2006059210A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 25, 2005</td><td class="patent-data-table-td patent-date-value">Jun 8, 2006</td><td class="patent-data-table-td ">Warner Lambert Co</td><td class="patent-data-table-td ">Fused bicyclic pyrrols as hmg-coa reductase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007057755A1?cl=en">WO2007057755A1</a></td><td class="patent-data-table-td patent-date-value">Nov 9, 2006</td><td class="patent-data-table-td patent-date-value">May 24, 2007</td><td class="patent-data-table-td ">Pfizer Prod Inc</td><td class="patent-data-table-td ">Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid magnesium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007074406A2?cl=en">WO2007074406A2</a></td><td class="patent-data-table-td patent-date-value">Jul 11, 2006</td><td class="patent-data-table-td patent-date-value">Jul 5, 2007</td><td class="patent-data-table-td ">Pharmena North America Inc</td><td class="patent-data-table-td ">Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008002591A2?cl=en">WO2008002591A2</a></td><td class="patent-data-table-td patent-date-value">Jun 26, 2007</td><td class="patent-data-table-td patent-date-value">Jan 3, 2008</td><td class="patent-data-table-td ">Amgen Inc</td><td class="patent-data-table-td ">Methods for treating atherosclerosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008093951A1?cl=en">WO2008093951A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 21, 2008</td><td class="patent-data-table-td patent-date-value">Aug 7, 2008</td><td class="patent-data-table-td ">Hanmi Pharm Ind Co Ltd</td><td class="patent-data-table-td ">Atorvastatin strontium salt and pharmaceutical composition comprising same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2009054682A2?cl=en">WO2009054682A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 23, 2008</td><td class="patent-data-table-td patent-date-value">Apr 30, 2009</td><td class="patent-data-table-td ">Astech Co Ltd</td><td class="patent-data-table-td ">Prodrug of atrovastatin by cholesterol&#39;s synthesis inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011088806A2?cl=en">WO2011088806A2</a></td><td class="patent-data-table-td patent-date-value">Jan 12, 2011</td><td class="patent-data-table-td patent-date-value">Jul 28, 2011</td><td class="patent-data-table-td ">Zentiva, K.S.</td><td class="patent-data-table-td ">A method of industrial production of an amorphous form of atorvastatin with a high specific surface area and its use in a dosage form</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011154755A1?cl=en">WO2011154755A1</a></td><td class="patent-data-table-td patent-date-value">Jun 8, 2011</td><td class="patent-data-table-td patent-date-value">Dec 15, 2011</td><td class="patent-data-table-td ">Nanoform Cardiovascular Therapeutics Ltd.</td><td class="patent-data-table-td ">Nanostructured atorvastatin, its pharmaceutically acceptable salts and compositions of them, process for the preparation thereof and pharmaceutical compositions containing them</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012015157A1?cl=en">WO2012015157A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 9, 2011</td><td class="patent-data-table-td patent-date-value">Feb 2, 2012</td><td class="patent-data-table-td ">Kyongbo Pharm. Co., Ltd.</td><td class="patent-data-table-td ">Novel crystalline form of atorvastatin hemi-calcium salt, hydrate thereof, and method of producing the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013004591A1?cl=en">WO2013004591A1</a></td><td class="patent-data-table-td patent-date-value">Jun 28, 2012</td><td class="patent-data-table-td patent-date-value">Jan 10, 2013</td><td class="patent-data-table-td ">Dsm Sinochem Pharmaceuticals Netherlands B.V.</td><td class="patent-data-table-td ">Micronized crystals of atorvastatin hemicalcium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013072770A2?cl=en">WO2013072770A2</a></td><td class="patent-data-table-td patent-date-value">Nov 14, 2012</td><td class="patent-data-table-td patent-date-value">May 23, 2013</td><td class="patent-data-table-td ">Dr. Reddy&#39;s Laboratories Ltd.</td><td class="patent-data-table-td ">Pharmaceutical formulations comprising atorvastatin and glimepiride</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013086443A1?cl=en">WO2013086443A1</a></td><td class="patent-data-table-td patent-date-value">Dec 7, 2012</td><td class="patent-data-table-td patent-date-value">Jun 13, 2013</td><td class="patent-data-table-td ">Amgen Inc.</td><td class="patent-data-table-td ">Agonistic human lcat antigen binding proteins and their use in therapy</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=4Z5MBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc548/defs548.htm&usg=AFQjCNEJR3l-3fNtZ4E4S53vEr85bVXOrQ#C548S537000">548/537</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=4Z5MBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S423000">514/423</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=4Z5MBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S429000">514/429</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=4Z5MBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D">C07D</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=4Z5MBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031000000">A61K31/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=4Z5MBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0043000000">A61P43/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=4Z5MBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0003140000">A61P3/14</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=4Z5MBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0003060000">A61P3/06</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=4Z5MBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0207340000">C07D207/34</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=4Z5MBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031400000">A61K31/40</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=4Z5MBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07D207/34">C07D207/34</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">C07D207/34</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">May 2, 2011</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">12</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">May 2, 2011</td><td class="patent-data-table-td ">SULP</td><td class="patent-data-table-td ">Surcharge for late payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">11</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 20, 2007</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 26, 2006</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">THE PATENTABILITY OF CLAIMS 3, 6-8, 14-15, 20-25, 30, 32-35, 37 AND 39-44 IS CONFIRMED. CLAIMS 1-2,4-5, 9, 28-29, 31, 36 AND 38 ARE DETERMINED TO BE PATENTABLE AS AMENDED. CLAIMS 10-13, 16-19 AND 26-27, DEPENDENT ON AN AMENDED CLAIM, ARE DETERMINED TO BE PATENTABLE. NEW CLAIMS 45-117 ARE ADDED AND DETERMINED TO BE PATENTABLE.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Nov 2, 2004</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20040917</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">May 7, 2003</td><td class="patent-data-table-td ">REMI</td><td class="patent-data-table-td ">Maintenance fee reminder mailed</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 31, 2003</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">May 29, 1998</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">WARNER-LAMBERT COMPANY, NEW JERSEY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">A CORRECTIVE COVERSHEET TO CORRECT ITEM 9 ON THE COVERSHEET RECORDED ON REEL 9008 FRAME 0633;ASSIGNORS:BRIGGS, CHRISTOPHER A.;JENNINGS, REX A.;WADE, ROBERT;AND OTHERS;REEL/FRAME:009229/0968;SIGNING DATES FROM 19950825 TO 19950904</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 2, 1997</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">WARNER-LAMBERT COMPANY, NEW JERSEY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRIGGS, CHRISTOPHER A.;JENNINGS, REX A.;WADE, ROBERT;ANDOTHERS;REEL/FRAME:009008/0633;SIGNING DATES FROM 19950825 TO 19950904</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U2XtQnzg_IZYHpI54uU-okKAY8AJg\u0026id=4Z5MBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U0qfsIkz_o4qAvF4lL0n23nGL5gRw\u0026id=4Z5MBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U3HyESFBe4wVBRaz4n3Ae99YbS5Vw","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Crystalline_R_R_R_2_4_Dfluorophenyl_β.pdf?id=4Z5MBAABERAJ\u0026output=pdf\u0026sig=ACfU3U1EfQimT28anhv3q73LRq9RhMkDXA"},"sample_url":"http://www.google.com/patents/reader?id=4Z5MBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>